Neos Therapeutics Inc (NASDAQ:NEOS)’s stock price was up 5.1% on Friday . The stock traded as high as $1.93 and last traded at $1.85, approximately 303,953 shares were traded during trading. A decline of 21% from the average daily volume of 384,034 shares. The stock had previously closed at $1.76.
Several analysts have recently weighed in on NEOS shares. Cantor Fitzgerald reduced their price objective on shares of Neos Therapeutics from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, June 12th. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. BMO Capital Markets reduced their price objective on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a research report on Monday, August 12th. Finally, ValuEngine upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Neos Therapeutics presently has an average rating of “Buy” and an average price target of $6.05.
The firm’s 50-day moving average price is $1.43 and its two-hundred day moving average price is $1.92. The company has a current ratio of 1.13, a quick ratio of 1.27 and a debt-to-equity ratio of 41.70.
A number of hedge funds have recently added to or reduced their stakes in NEOS. BNP Paribas Arbitrage SA raised its position in Neos Therapeutics by 1,749.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock valued at $26,000 after purchasing an additional 9,552 shares during the last quarter. Alambic Investment Management L.P. purchased a new stake in Neos Therapeutics in the 1st quarter valued at $32,000. Weiss Asset Management LP purchased a new stake in Neos Therapeutics in the 2nd quarter valued at $36,000. Acadian Asset Management LLC purchased a new stake in Neos Therapeutics in the 2nd quarter valued at $40,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in Neos Therapeutics in the 2nd quarter valued at $57,000. Hedge funds and other institutional investors own 54.88% of the company’s stock.
Neos Therapeutics Company Profile (NASDAQ:NEOS)
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.